CELH: The most recent relevant announcement from Celsius was the positive preliminary look at the first quarter numbers which finally show a positive trend in recent sales, although the number was still down from the first quarter of the previous year.
The company has been mentioned as a competitor, however, in three recent earnings summaries published by 'The Wall St Cheat Sheet' about the big boys in the beverage sector (Pepsi, Dr. Pepper and Coca-Cola).
At first it looked like it may have been a ploy by the company to have its name thrown around as a competitor to those big players, but The Cheat Sheet has become the master of throwing as many stock symbols as humanly possible on everything they publish, usually by adding the symbols of 'competitors' to each company they write about.
Good way to earn clicks, but that's about it. Although many stocks are getting mention from these tactics, there's little relevance applied.
Bear in mind, the only relevant news from CELH will relate to earnings or a potential partnership or buyout.
The Wall St Cheat Sheet is new to the Yahoo! headlines, from what I've noticed, but the reputation is already there - The Wall Street Click Seekers.
Disclosure: Long CELH.
TLON: Talon Pharmaceuticals received mention on my 'Weekly Stock Watch' list at VFC's NEW Stock House over the weekend after the stock realized rapid gains from well under a buck to well over a buck in just a short period of time (article was later republished on Seeking Alpha).
The stock opened Monday morning up rather signficantly in a rise to $1.50, which offered an opportune time for investors in at a buck or below to flip a few trading shares.
Now, back to trading for roughly $1.30 - this will be one to watch.
The potential is there for the run to continue, as this may be a re-grouping/consolidation phase after such a significant run, but keep in mind this is still a highly speculative play and each investor should conduct his or her own DD and invest accordingly.
As mentioned over the weekend, the recent financing deal could be an indication that someone believes this company has a future.
That said, I get the impression that the day/swing/momentum traders are playing this thing right now - will be looking to get back in.
Disclosure: No position.
CVM: Last week it was India and Canada, this week it's Taiwan.
Cel-Sci issued another press release regarding the commencement of the Multikine Phase III trial on Tuesday, this one identifying that Taiwan has given the go-ahead to start enrolling patients.
For those that did not consider the Cel-Sci PR eventful enough, it did spark a comment from TheStreet.com's biotech blogger.
In his rebuttal blog post, the biotech blogger attempted to poke fun at Cel-Sci's PR guy for issuing updates to shareholders and potential shareholders; a pretty weak blog post for a guy who considers himself a journalist.
No mention how well his kids are doing on geography, however, since I do remember him at one point informing readers that he was using Cel-Sci PRs to teach his kids geography.
And he can count, too. He counted up to 16 and proudly boasted about it as blog post title.
That's about worse than his comments last week that the pending Spectrum Pharmaceuticals FDA approval decision was garnering more hype than the royal wedding in the UK.
Think it's about time this guy breathes a bit of fresh air; it's good to be 'into' the sector you cover in your blog, but not be consumed by it. When you believe that Spectrum is being hyped like a royal wedding, and when you're using biotech PRs to teach your kids - you're a little bit consumed, I think.
As for Cel-Sci - a speculative cancer immunotherapy stock in a highly speculative sector that holds the world of potential should Multikine work. Dendreon was once a company and a stock like that when its own product - Provenge - was in Phase III. And the same biotech blogger told everyone that it, too, was a wasted investment.
Funny thing is, when Provenge was approved, his tune changed. In fact, when comparing another cancer immunotherapy stock to Dendreon a short time later, the biotech blogger claimed that "I know Dendreon."
Ironic how that works. Was it the Dendreon he knew before or after he told us all it would fail?
It's all about risk/reward, and CVM is a nice risk/reward play, in my opinion, and might even give you a decent spike to sell into once in a while to flip a few trading shares.
The biotech blogger has considerably toned down his posts recently, but toned down or not, they're still far from what one one expect from someone claiming to partake in 'journalism'.
It may look like I don't like this guy; that's not the case. I think we all have a responsibility to make ourselves better - especially those that are out there claiming to be journalists. If you take a look at foreign affairs right now, questionable and irresponsible "journalism" has fueled and inflamed crisis in multiple regions and has led to misinformation (at best) and outright lies (at worst) being re-broadcast on multiple media sites.
Most mainstream media outlets even published a fake photo of a dead Bin Laden without even checking to ensure it was real.
Questionable practices influence stock prices all the time, as well.
With the influence (although waning influence) that TheStreet.com has (or had), you'd think that a standard would be kept. Calling people that disagree with you 'retards' isn't much of a standard. Especially - again - for someone calling himself a journalist.
That's more the style of Mike Lupica from the New York Daily News.
Journalism is not blogging, and blogging is what TheStreet does.
That simple.
Disclosure: Long CVM.
